Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 611 (MIR611)
- Target
- MIR611
- Molecular classification
- MicroRNA, Non-coding RNA, RNA regulatory molecule
01
Overview
microRNA 611 is a human microRNA (miRNA) belonging to the non-coding RNA family, typically processed from a primary transcript by Drosha and further by Dicer, then loaded into the RISC complex. It functions mainly to downregulate specific target mRNAs via base pairing and subsequent silencing mechanisms. MIR611 participates in critical cellular processes such as inhibiting EMT and migration in lung cancer by antagonizing MAPKAP1 and modulating the AKT pathway, with its expression inversely correlated with metastatic potential and overall survival in tumors. Its regulatory actions make it a candidate therapeutic and biomarker target in oncology
- Other names
- hsa-mir-611MIRN611MIR611microRNA-611miR-611
02
Mechanism of action
Inhibits EMT and migration by targeting and downregulating MAPKAP1, affecting AKT pathway activation in lung cancer cells\nmiR-611 acts as a gene silencer through RNA-induced silencing complex (RISC) recruitment
03
Biological functions
Regulation of gene expression (through mRNA silencing)Inhibition of epithelial-mesenchymal transition (EMT)Modulation of cell migrationPotential influence on the MAPKAP1/AKT pathway in cancer
04
Disease associations
Cancer (particularly lung cancer metastasis and progression)Possibly involved in disease states where EMT and cell migration are relevant
05
Safety considerations
No direct safety concerns are documented for targeting MIR611 itselfTherapeutic manipulation of miRNAs in general may cause off-target effects due to broad regulatory functions in cellular pathways
06
Biomarkers
Expression levels of miR-611 in lung cancer tissues may serve as a biomarker for metastasis risk and overall survival predictionPotential biomarker for monitoring therapeutic efficacy in interventions that modulate EMT or MAPKAP1/AKT signaling
Beyond the preview
Go deeper on microRNA 611 (MIR611).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA 611 (MIR611).